Humacyte (HUMA) vs Sutro Biopharma (STRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Sutro Biopharma (STRO) has outperformed Humacyte (HUMA) over the past year, gaining 2.4% versus a loss of 63.5%. Over five years, STRO leads with a -94.7% price change compared with -95.9% for HUMA. Sutro Biopharma is the larger company by market cap ($142.8 million vs $123.7 million), about 1.2 times the size.
Sutro Biopharma converts more of its revenue into profit, with a net margin of -186.5% versus -2003.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HUMA | STRO |
|---|---|---|
| Share price | $0.4454 | $8.60 |
| Market cap | $123.73M | $142.77M |
| 1-day change | -17.90% | -1.38% |
| YTD return | -53.65% | -25.67% |
| 1-year return | -63.49% | +2.38% |
| 5-year return | -95.94% | -94.68% |
| EPS (TTM) | $-0.45 | $-12.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.04M | $102.48M |
| Revenue growth (YoY) | — | +65.18% |
| Net income (latest FY) | $-40.83M | $-191.09M |
| Gross margin | -376.05% | — |
| Operating margin | -5306.04% | -154.53% |
| Net margin | -2003.58% | -186.45% |
| 52-week high | $1.53 | $43.85 |
| 52-week low | $0.337 | $7.15 |
| Distance from 52-week high | -70.79% | -80.39% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +268.21% | +419.65% |
| Average volume | 5.36M | 304.90K |
| Shares outstanding | 277.80M | 16.60M |
| Employees | 184 | 129 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- STRO has outperformed HUMA by 65.9 percentage points over the past year.
- Sutro Biopharma is more profitable, keeping -186.5 cents of every revenue dollar as net income versus -2003.6 cents for Humacyte.
About Humacyte
HUMA stock →Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 184 employees
About Sutro Biopharma
STRO stock →Sutro Biopharma, Inc. operates as an oncology company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 129 employees
HUMA vs STRO FAQ
Which is bigger, Humacyte or Sutro Biopharma?
Sutro Biopharma (STRO) is larger, with a market capitalization of $142.77M compared with $123.73M for Humacyte (HUMA).
Which stock has performed better over the past year, HUMA or STRO?
STRO returned +2.38% over the past 12 months, compared with -63.49% for HUMA (price return, excluding dividends). Past performance does not predict future results.
Are Humacyte and Sutro Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.